Midwest Capital Advisors LLC Lowers Stake in Eli Lilly and Company $LLY

Midwest Capital Advisors LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 236 shares of the company’s stock after selling 40 shares during the period. Midwest Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $184,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter valued at about $27,000. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $40,000. Finally, TD Capital Management LLC grew its position in shares of Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Guggenheim upped their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Leerink Partners reissued a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $948.06.

Insiders Place Their Bets

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY opened at $833.08 on Monday. The firm has a market capitalization of $788.47 billion, a PE ratio of 54.45, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company’s fifty day moving average price is $742.42 and its 200-day moving average price is $765.55.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.